We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
J&J to Pay $572M in Opioid Case; Plus Case-Shiller Home Price Read
Read MoreHide Full Article
Tuesday, August 27, 2019
Again, here at the end of August, we mostly wait for a time of more populous economic data; in a week, we’ll start seeing things like new jobs reports from the month of August. Until then, we sift through tea leaves until we can land on something new and concrete…
Which brings us to Norman, Oklahoma, where Johnson & Johnson (JNJ - Free Report) has been ruled against in a major opioid epidemic landmark case. The pharma giant now owes $572 million, as per the judge in this case, which pits J&J responsible for rampant opioid use beyond responsible levels. The other two companies originally named in the case — Teva (TEVA - Free Report) and Purdue Pharma — had already settled for $85 million and $270 million, respectively.
However, shares are up roughly 1% in today’s pre-market for J&J, as analysts following the trial and other newsworthy items amid the U.S. opioid epidemic expected as much as a $17 billion charge to J&J in the case. Wall Street had priced in $1-2 billion. So even though J&J has been ruled to pay more than double Purdue’s settlement — J&J will no doubt be appealing this ruling — the dollar amount is still well below what many investors were fearing.
Not only J&J, but other pharma companies that provide opiates for patients — Teva, Mallinckrodt , Endo International — are all up 3% in today’s pre-market. That said, the Oklahoma case is but the tip of the iceberg; analysts now look toward a new trial in Ohio this October on opioid abuse and pharma companies’ involvement in it. For that case, J&J is already openly discussing settlement options.
Case-Shiller Home Prices Up, but Slower
The late read (from June) — but deemed most accurate — on U.S. home prices from the latest Case-Shiller index showed home prices continuing to rise, but lower than in recent months. A headline of +3.1% annually is 20 basis points lower than the read for May. The 10-City index rose 1.8% while the 20-City was +2.1%, both down from the 2.2% and 2.4% in the previous month, respectively).
Leading cities were some of the usual suspects: Phoenix led the way in June home pricing, +5.8%, followed by Las Vegas at 5.5% and Tampa at 4.7%. Analysts cite hopefulness for future reads, with lower mortgage rates hopefully having spurred home prices in the later summer months. But, of course, we will need to wait a while to see if these expectations will have come to fruition.
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
J&J to Pay $572M in Opioid Case; Plus Case-Shiller Home Price Read
Tuesday, August 27, 2019
Again, here at the end of August, we mostly wait for a time of more populous economic data; in a week, we’ll start seeing things like new jobs reports from the month of August. Until then, we sift through tea leaves until we can land on something new and concrete…
Which brings us to Norman, Oklahoma, where Johnson & Johnson (JNJ - Free Report) has been ruled against in a major opioid epidemic landmark case. The pharma giant now owes $572 million, as per the judge in this case, which pits J&J responsible for rampant opioid use beyond responsible levels. The other two companies originally named in the case — Teva (TEVA - Free Report) and Purdue Pharma — had already settled for $85 million and $270 million, respectively.
However, shares are up roughly 1% in today’s pre-market for J&J, as analysts following the trial and other newsworthy items amid the U.S. opioid epidemic expected as much as a $17 billion charge to J&J in the case. Wall Street had priced in $1-2 billion. So even though J&J has been ruled to pay more than double Purdue’s settlement — J&J will no doubt be appealing this ruling — the dollar amount is still well below what many investors were fearing.
Not only J&J, but other pharma companies that provide opiates for patients — Teva, Mallinckrodt , Endo International — are all up 3% in today’s pre-market. That said, the Oklahoma case is but the tip of the iceberg; analysts now look toward a new trial in Ohio this October on opioid abuse and pharma companies’ involvement in it. For that case, J&J is already openly discussing settlement options.
Case-Shiller Home Prices Up, but Slower
The late read (from June) — but deemed most accurate — on U.S. home prices from the latest Case-Shiller index showed home prices continuing to rise, but lower than in recent months. A headline of +3.1% annually is 20 basis points lower than the read for May. The 10-City index rose 1.8% while the 20-City was +2.1%, both down from the 2.2% and 2.4% in the previous month, respectively).
Leading cities were some of the usual suspects: Phoenix led the way in June home pricing, +5.8%, followed by Las Vegas at 5.5% and Tampa at 4.7%. Analysts cite hopefulness for future reads, with lower mortgage rates hopefully having spurred home prices in the later summer months. But, of course, we will need to wait a while to see if these expectations will have come to fruition.
Mark Vickery
Senior Editor
Questions or comments about this article and/or its author? Click here>>
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>